First Trust Advisors LP Has $2.17 Million Stake in Celldex Therapeutics, Inc. $CLDX

First Trust Advisors LP boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 78.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,470 shares of the biopharmaceutical company’s stock after purchasing an additional 30,157 shares during the period. First Trust Advisors LP’s holdings in Celldex Therapeutics were worth $2,172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its holdings in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Celldex Therapeutics by 6.9% in the fourth quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock valued at $325,000 after purchasing an additional 773 shares during the last quarter. Panagora Asset Management Inc. raised its position in shares of Celldex Therapeutics by 7.5% in the fourth quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company’s stock valued at $594,000 after purchasing an additional 1,522 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Celldex Therapeutics in the third quarter valued at about $42,000.

Analyst Ratings Changes

CLDX has been the subject of a number of research reports. Cantor Fitzgerald cut their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Barclays increased their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Guggenheim raised their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Finally, Canaccord Genuity Group reduced their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $55.46.

Celldex Therapeutics Stock Performance

CLDX opened at $41.71 on Friday. The stock has a fifty day moving average of $35.19 and a 200-day moving average of $31.54. The company has a market capitalization of $3.27 billion, a P/E ratio of -9.59 and a beta of 0.87. Celldex Therapeutics, Inc. has a fifty-two week low of $19.72 and a fifty-two week high of $42.92.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. On average, equities research analysts predict that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.